# Molecular Characterization of Acute Erythroid Leukemia (M6-AML) Using Targeted Next-generation Sequencing

> **NCT02861651** · — · COMPLETED · sponsor: **Institut Paoli-Calmettes** · enrollment: 40 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **OTHER:** DNA sequencing

## Key facts

- **NCT ID:** NCT02861651
- **Lead sponsor:** Institut Paoli-Calmettes
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-07
- **Final completion:** —
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2016-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02861651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02861651, "Molecular Characterization of Acute Erythroid Leukemia (M6-AML) Using Targeted Next-generation Sequencing". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02861651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*